focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.25
Bid: 1.10
Ask: 1.40
Change: 0.00 (0.00%)
Spread: 0.30 (27.273%)
Open: 1.25
High: 1.25
Low: 1.25
Prev. Close: 1.25
PYC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Termination of Equity Swap Agreement

2 Feb 2015 07:00

RNS Number : 6927D
Physiomics PLC
02 February 2015
 

 

 

 

Physiomics plc

("Physiomics") or ("the Company")

 

Termination of Equity Swap Agreement

 

 

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that, by mutual agreement, it has terminated its Equity Swap Agreement with YA Global Master SPV, Ltd. ("YAGM"), previously announced on 25th July 2014. YAGM will remain as ordinary shareholders but with no further obligations under the SWAP agreement. YAGM remains a supportive shareholder in Physiomics and we have been advised that it has placed the shares onto its long book.

Dr Mark Chadwick, CEO of Physiomics, commented: "We are pleased to have concluded this agreement by mutual agreement."

 

Enquiries:

 

Physiomics plc

Dr Mark Chadwick, CEO

+44 (0)1865 784 980

 

 

WH Ireland Limited (broker/nomad)

Katy Mitchell

+44 (0) 161 832 2174

 

 

About Physiomics plc

 

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million1.

 

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

 

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

 

SystemCell® is a registered trademark of Physiomics plc

1Tufts Centre Impact Report 2002

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRBBMATMBIJBAA
Date   Source Headline
31st Mar 20067:00 amPRNInterim Results
22nd Dec 20051:04 pmPRNAGM Statement
25th Oct 20053:02 pmPRNStatement re: Partial Investing of Share Options
18th Oct 200512:06 pmPRNDirector/PDMR Shareholding
8th Sep 20056:00 amPRNFinal Results
26th Aug 20056:00 amPRNDirectorate Change
28th Jun 200510:48 amPRNAdditional Listing
27th Jun 20056:00 amPRNStatement re share subscription and issue of options
23rd Jun 20056:00 amPRNRe Agreement
21st Mar 20057:00 amPRNInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.